[Thrombin generation assay in autoimmune disease].

Area of Science:

• Coagulation science
• Immunology
• Cardiovascular risk assessment

Background:

• Thrombin generation assay (TGA) evaluates coagulation initiation, propagation, and inhibition.
• TGA assesses hemorrhagic risk in hemophilia and hypercoagulable states.
• Cardiovascular risk is linked to autoimmune diseases (AID) like antiphospholipid syndrome.

Purpose of the Study:

• To explore the utility of TGA in evaluating cardiovascular risk in AID.
• To assess TGA's role in hypercoagulable states associated with AID.
• To investigate TGA's correlation with disease activity in specific AIDs.

Main Methods:

• Utilized TGA to measure thrombin generation.
• Compared TGA in antiphospholipid syndrome patients on rivaroxaban versus warfarin.
• Measured TGA in rheumatoid arthritis, systemic lupus erythematosus, and Behçet's disease.

Main Results:

• TGA identified hypercoagulability in antiphospholipid syndrome.
• Elevated TGA was observed in rheumatoid arthritis, systemic lupus erythematosus, and Behçet's disease without thrombotic events.
• TGA correlated with inflammatory activity in rheumatoid arthritis and disease activity in systemic lupus erythematosus and Behçet's disease.

Conclusions:

• TGA is underutilized in clinical AID evaluation but shows potential.
• TGA can help measure AID activity due to the coagulation-inflammation link.
• Standardization is needed for broader TGA interpretation in AID.